The 12
companies included in the HIV/AIDS arm of the 2021 ‘Corporate Reputation of
Pharma’ analyses:
AbbVie I Bristol Myers Squibb I Gilead Sciences I GSK I Janssen I Merck
& Co* I Mylan I Roche** I Sandoz I Sanofi I Teva I ViiV Healthcare
·
* Known as MSD outside of the United States
and Canada.
·
** Known as Genentech in the United States,
and as Chugai in Japan.
Chart 1. The
number of respondent HIV/AIDS patient groups familiar, or working,
with the companies listed above [https://bit.ly/3aTuQbB].
Click here to read more
about PatientView’s methodology for the ‘Corporate Reputation
of Pharma’ 2021 (published 2022).
SUMMARY
OF RESULTS
FINDINGS
AT INDUSTRY LEVEL
The 168
HIV/AIDS patient groups responding to the 2021 ‘Corporate Reputation’
survey rated the pharma industry more favourably for corporate reputation
than their predecessors in all previous years. 50%
of 2021’s respondent HIV/AIDS patient groups stated that the industry had
an “Excellent” or “Good” corporate reputation, against 47% saying the same
in 2020—although both of these figures remain lower than those reported by
patient groups of other therapy areas. In 2021, 59% of respondent patient
groups from all therapy areas thought the pharma industry had an
“Excellent” or “Good” corporate reputation.
The pharmaceutical industry has always had
to respond to an active and effective patient movement that represents
people with HIV/AIDS. However, the recent increases in pharma’s corporate
reputation over the last two years can, in part, be attributed to the
industry’s response to the Covid-19 pandemic. 78% of 2021’s respondent HIV/AIDS patient
groups judged the industry’s response to Covid-19 to be “Effective” or
“Very effective”. Although
pharma’s relationships with patient groups are wide ranging, funding became
an existential issue for patient groups during the pandemic. In 2021, 65%
of the 142 respondent HIV/AIDS patient groups working with pharma stated
that they had received financial donations. 2020’s equivalent figure was
57%.
Despite
the higher approval ratings for pharma from the HIV/AIDS patient groups
responding to the 2021 ‘Corporate Reputation’ survey, these patient groups
also expressed concerns that the industry should be doing much more. Although pharma has made significant
therapeutic advances over the past 40 years, the fact remains that almost
38 million people worldwide continue to live with HIV. International bodies
have set the goal of ending the epidemic by 2030. The pharmaceutical
industry has an important role to play in supporting these efforts,
according to respondent HIV/AIDS patient groups, as follows:
·
Innovation: 68% of the HIV/AIDS patient groups
responding to the 2021 ‘Corporate Reputation’ survey thought the industry
“Excellent” or “Good” at innovation (versus 58% saying the same in 2020).
Also in 2021, 72% of respondent HIV/AIDS groups considered the industry
“Excellent” or “Good” at creating products of benefit to patients (versus
58% saying the same in 2020). Nonetheless, as the world aims to eliminate
the HIV/AIDS epidemic, respondent HIV/AIDS patient groups call for further
improvements to pharma’s drug treatments, so that people living with
HIV/AIDS can take their medication with minimal difficulty (improve
compliance), and, at the same time, enjoy a good quality of life.
“Investigar en más fármacos y opciones terapéuticas,
para la mejora de la calidad de vida de las personas. Invertir en vacunas
tanto preventivas como terapéuticas. Mejorar los efectos secundarios de los
fármacos y sus interacciones farmacológicas.” (“Investigate more drugs
and therapeutic options to improve people’s quality of life. Invest in both
preventive and therapeutic vaccines. Improve the side effects of drugs, and
their drug interactions.”) —Regional
HIV/AIDS patient group, Spain
·
Access to medicines: Just 33%
of 2021’s respondent HIV/AIDS patient groups thought the industry
“Excellent” or “Good” at helping to ensure equitable access to medicines.
Of the estimated 37.7 million people living with HIV in 2020, only 75% were
accessing anti-retroviral treatment—leaving 9.5 million individuals
(predominantly in poorer countries) still waiting. In June 2021, UNAIDS
issued a new global pledge “to end all inequalities faced by communities
and people affected by HIV towards ending AIDS.” [https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2021/june/20210608_hlm-opens]
“Facilitar o acesso aos medicamentos à
comunidade de baixa renda.”(“Facilitate access to medicines for the
low-income community.”)—National
HIV/AIDS patient group, Brazil
·
Drug pricing and transparency: Some
respondent HIV/AIDS patient groups blame the current inequitable situation
on the ineffective processes by which governments negotiate drug prices
with pharma, and pharma’s lack of transparency in that process. Since 2013,
respondent HIV/AIDS patient groups have consistently marked pharma down for
its pricing policies—in 2021, only 18% thought the industry “Excellent” or
“Good” at setting fair prices. Similarly, just 16% thought pharma
“Excellent” or “Good” at being transparent about pricing.
“Para efeitos de perceção da integridade, a indústria
farmacêutica deveria flexibilizar as condições negociais, tendo em consideração
a importância vital de alguns dos seus produtos no garante da sobrevivência
das populações, nomeadamente através da conceção de patentes.” (“For
the sake of the perception of integrity, the pharmaceutical industry should
make its negotiating terms more flexible, taking into consideration the
vital importance of some of its products in ensuring the survival of
populations, specifically through the granting of patents.”) —International
HIV/AIDS and hepatitis patient group, Portugal
COMPANY RANKINGS
The
top-three pharma companies out of 12 companies, ranked for
their overall corporate reputation in 2021, assessed by respondent HIV/AIDS patient groups familiar
with the company: ViiV Healthcare, 1st | Gilead Sciences, 2nd |
and Janssen, 3rd.
The
top-three ‘big-pharma’ companies out of 7
companies, ranked for overall corporate reputation in
2021, assessed by respondent HIV/AIDS patient groups familiar with
the company: Janssen, 1st | GSK, 2nd |
and Merck &Co*, 3rd.
*
known as MSD outside of the United States and Canada
PROFILE OF 2021’S RESPONDENT HIV/AIDS PATIENT GROUPS
Chart 2:
Geographic location of respondent HIV/AIDS patient groups, 2021
|
No comments:
Post a Comment